Last reviewed · How we verify
AZD6244 Dosing Period 4
AZD6244 is a selective inhibitor of MEK1/2, which are key components of the RAS-RAF-MEK-ERK signaling pathway.
AZD6244 is a selective inhibitor of MEK1/2, which are key components of the RAS-RAF-MEK-ERK signaling pathway. Used for Advanced solid tumors with RAS or BRAF mutations.
At a glance
| Generic name | AZD6244 Dosing Period 4 |
|---|---|
| Also known as | AZD6244 |
| Sponsor | AstraZeneca |
| Drug class | MEK inhibitor |
| Target | MEK1/2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
By inhibiting MEK1/2, AZD6244 blocks the activation of ERK, leading to reduced proliferation and survival of cancer cells that depend on this pathway.
Approved indications
- Advanced solid tumors with RAS or BRAF mutations
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (PHASE1)
- A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD6244 Dosing Period 4 CI brief — competitive landscape report
- AZD6244 Dosing Period 4 updates RSS · CI watch RSS
- AstraZeneca portfolio CI